ERBB2 and neoplasm: In 2011, the Nb 2Rs15d labeled with 99mTc was first described, showing high uptake in two HER2+ mouse tumor models at 1 h post-injection, while binding a distinct epitope from the anti-HER2 therapeutic mAbs trastuzumab and pertuzumab [36].